Corbus Pharmaceuticals Q3 EPS $(2.27) Misses $(2.06) Estimate
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals reported Q3 losses of $(2.27) per share, missing the analyst consensus estimate of $(2.06) by 10.19 percent. This represents a 8.1 percent decrease over losses from the same period last year.
November 07, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Corbus Pharmaceuticals' Q3 earnings per share (EPS) missed analyst estimates by 10.19%, and decreased by 8.1% compared to the same period last year.
Corbus Pharmaceuticals' Q3 earnings missed analyst estimates, which is typically a negative signal to the market. The decrease in earnings compared to the same period last year further exacerbates this negative sentiment. This could lead to a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100